Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Darolutamide is developed jointly by Bayer and Orion Corporation
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
Resolv ER may remedy leading causes of blindness in adults
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Subscribe To Our Newsletter & Stay Updated
